The establishment of a novel 'real paclitaxel-sensitive' cell line from a patient suffered from IV stage-ovarian carcinoma.

• Project/Area Number: 19591923
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: University of Tsukuba
• Principal Investigator: OKI Akinori University of Tsukuba, 大学院・人間総合科学研究科, 教授 (60334067)
• Co-Investigator(Kenkyū-buntansha): YOSHIKAWA Hiroyuki 筑波大学, 大学院・人間総合科学研究科, 教授 (40158415)
• Project Period (FY): 2007 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 卵巣癌 / 細胞株 / 抗癌剤感受性 / パクリタキセル / 抗癌剤高感受性 / 抗癌剤感受性検査

Research Abstract

Although CBDCA/Paclitaxel(PTX) therapy(CP therapy), or new anti-neoplastic agents such as topotecan and doxil contribute to some improvement on the survival of advanced ovarian carcinomas, it is far from complete control of the disease. However, many of us have been experienced dramatic clinical complete response(CR) cases that resulted to be cured by intensive combination therapy. This is a streak of hope for not only patients, but us as the cancer therapists. A novel cell line, named Opt203 was established from a patient who was suffered from IV stage ovarian carcinoma and successfully treated with 10 courses of CP therapy and two times of interval cytoreductive surgeries, resulted to complete response and maintained the status of no evidence of recurrence(NER) for 20 months. In the study of the characterization of this cell line, we found that Opt203 was very chemo-sensitive against many anti-neoplastic agents, especially paclitaxel(PTX). This result is closely concerned to the clinical course of the original patient. Thus Opt203 line was regarded as "real PTX-sensitive" cell line, and would be a bench mark of PTX sensitive cell line in vitro.

Research Products

• [Journal Article] Interleukin-10 21082 Gene Polymorphism and Susceptibility to Cervical Cancer Among Japanese Women (2010)
  • Author(s): K.Matsumoto, A.Oki, T.Satoh, S.Okada, T.Minaguchi, M.Onuki, H.Ochi, S.Nakao, M.Sakurai, A.Abe, H.Hamada, H.Yoshikawa
  • Journal Title: Jpn J Clin Oncol 40(11) Pages: 1113-1116
  • Peer Reviewed
• [Journal Article] MRI of Endometriotic Cysts in Association With Ovarian Carcinoma. (2010)
  • Author(s): YO Tanaka, S.Okada, T.Yagi, T.Satoh, A.Oki, H.Tunoda, H.Yoshikawa
  • Journal Title: Am J Roentgenol 194(2) Pages: 355-361
  • Peer Reviewed
• [Journal Article] Silent venous thromboembolism before treatment in endometrial cancer and the risk factors. (2008)
  • Author(s): T.Satoh, K.Matsumoto, K.Uno, M.Sakurai, S.Okada, M.Onuki, T.Minaguchi, YO Tanaka, S.Homma, A.Oki, H.Yoshikawa
  • Journal Title: Br J Cancer 99(7) Pages: 1034-1039
  • Peer Reviewed
• [Presentation] 化学療法で完全寛解)CR)した進行卵巣癌由来細胞株からの単細胞クローン株の樹立 (2010)
  • Author(s): 沖明典、安部加奈子、田中勝洋、岩城真奈美、安倍梓、中尾砂理、小貫麻美子、水口剛雄、岡田智志、松本光司、佐藤豊実、吉川裕之
  • Organizer: 第62回日本産科婦人科学会学術講演会
  • Place of Presentation: 東京
• [Presentation] 化学療法で感染寛解(CR)した進行卵巣がん由来細胞株からの単細胞クローン株の樹立 (2010)
  • Author(s): 沖明典
  • Organizer: 第62回日本産科婦人科学会学術講演会
  • Place of Presentation: 東京
• [Presentation] PTX/CBDCA(TC)療法で寛解した卵巣癌IV期症例由来の癌細胞株の樹立とその抗癌剤感受性 (2009)
  • Author(s): 沖明典、田坂暢崇、中村優子、櫻井学、安倍梓、中尾砂里、小貫麻美子、水口剛雄、岡田智志、松本光司、佐藤豊実、吉川裕之
  • Organizer: 第47回日本癌治療学会学術集会
  • Place of Presentation: 横浜
• [Presentation] IV期卵巣癌がCRになるには (2007)
  • Author(s): 沖 明典
  • Organizer: 第59回日本産科婦人科学会総会 学術講演会
  • Place of Presentation: 京都国際会議場
  • Year and Date: 2007-04-15